表紙
市場調查報告書
商品編碼
980945

膽管癌症 (BTC) :市場考察、流行病學、市場預測 (∼2030年)

Biliary Tract Cancers (BTCs)- Market Insight, Epidemiology and Market Forecast -2030

出版日期: 按訂單生產 | 出版商: DelveInsight Business Research LLP | 英文 325 Pages | 商品交期: 2-10個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

今後數年,膽管癌症市場,預計對這個病的全球性意識高漲和醫療保健費增加變化。據此,預計市場規模擴大,醫藥品企業對市場更加滲透。企業和學者,評價課題,摸索可能影響膽管癌症的研究開發的機會。開發中的治療方法,以治療/改善病情的新方法為焦點。主要企業,介入膽道癌症的治療藥的開發。一般認為新的治療藥的開始,對膽道癌症市場帶來大幅影響。

本報告提供美國,歐洲5個國家 (德國,西班牙,義大利,法國,英國) ,及日本等7個主要市場上膽管癌症 (BTC) 市場相關調查,市場概要,目前治療方法,新藥,各治療方法的市場佔有率,及市場規模預測等,市場成長的推動要素與阻礙,未滿足需求,機會潛在的可能性等相關分析。

目錄

第1章 重要的洞察

第2章 膽管癌症 (BTC)的市場概要

  • 市場佔有率(%)分佈
  • 市場佔有率(%)分佈預測

第3章 摘要整理

第4章 組織

第5章 膽管癌症 (BTC):疾病的背景和概要

  • 簡介
  • 膽管癌症的分類
  • 分期
    • 肝內CCA(iCCA)
    • Perihilar CCA
    • 遠位肝外
    • 膽囊癌症
  • 症狀
  • 病因
  • 發病機制
  • 生物標記
  • 診斷
    • 肝內CCA的診斷
    • 肺門周圍及遠位CCA的診斷
    • 膽囊癌症的診斷
    • 肝內膽管癌症診斷的指南
    • 膽道癌症診斷的ESMO診療指南

第6章 流行病學和患者人口

  • 主要調查結果
  • 主要7個市場上BTC的發病者總數
  • 前提條件與理論性根據:主要7個市場
  • 美國的流行病學
    • 發病總數
    • 年齡
    • 突然變異特異性
    • 分期
  • 德國的流行病學
  • 法國的流行病學
  • 義大利的流行病學
  • 西班牙的流行病學
  • 英國的流行病學
  • 日本的流行病學

第7章 治療和治療策略

    • 治療的推薦事項:British Society of Gastroenterology的指南
    • 肝內膽管癌症治療的指南
    • 膽管癌症的治療和後續行動的ESMO診療指南
    • 肝膽道癌症相關NCCN指南
    • 治療流程

第8章 病患歷程

第9章 調查的優先事項

第10章 未滿足需求

第11章 成藥

  • Pemigatinib: Incyte Corporation
    • 藥的說明
    • 法規當局的認證
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Larotrectinib: Loxo Oncology/Bayer
  • Entrectinib: Roche
    • 產品說明

第12章 新治療方法

  • Ivosidenib:Agios Pharmaceuticals
    • 產品說明
    • 其他開發活動
    • 臨床開發
    • 安全性和有效性
    • 產品簡介
  • Infigratinib: QED Therapeutics
  • Melphalan: Delcath Systems
  • Derazantinib: Basilea Pharmaceutica
  • Regorafenib: Bayer
  • Erdafitinib: Janssen Pharmaceutical
  • Opaganib: RedHill Biopharma
  • Fimaporfin: PCI biotech
  • KA2507: Karus Therapeutics
  • Lenvatinib: Eisai
  • Telotristat ethyl: Lexicon Pharmaceuticals/TerSera Therapeutics
  • DKN-01: Leap Therapeutics
  • Niraparib (Zejula): GlaxoSmithKline
  • E7090: Eisai
  • A166: KLUS Pharma
  • Durvalumab: AstraZeneca
  • Pembrolizumab: Merck Sharp & Dohme Corp.
  • Futibatinib: Taiho Oncology
  • Nab-paclitaxel: Celgene
  • Surufatinib: Hutchison Medipharma Limited
  • Bintrafusp Alfa: Merck Sharp & Dohme Corp.
  • Entinostat: Syndax Pharmaceuticals
  • Zanidatamab: BeiGene
  • Nivolumab: Bristol-Myers Squibb
  • TAS 102: Taiho Pharma
  • Nanoliposomal irinotecan: Ipsen
  • Trastuzumab deruxtecan (T-DXd): Daiichi Sankyo
  • NUC-1031:NuCana

第13章 膽管癌症:市場預測

  • 主要調查結果
  • 主要7個市場的BTC的市場規模

第14章 市場預測:主要7個市場

  • 美國的市場規模
    • 美國的BTC的整體市場規模
    • 市場規模:早期階段疾病的各治療法
    • 市場規模:第一選擇的進行性及轉移性病例的各治療法
    • 市場規模:第二選擇的進行性及轉移性病例的各治療法
  • 德國的市場規模
  • 法國的市場規模
  • 義大利的市場規模
  • 西班牙的市場規模
  • 英國的市場規模
  • 日本的市場規模

第15章 市場促進因素

第16章 市場障礙

第17章 償付和市場進入

第18章 SWOT分析

第19章 案例研究

  • 年輕的男性的肝內膽管癌症的病例報告
  • 對固態腫瘤的新潛在性免疫療法藥:案例研究
  • 2個切除決斷邊陽性伴隨的遠位肝外膽管癌範例

第20章 KOL的見解

第21章 附錄

第22章 報告的調查手法

第23章 DelveInsight的服務內容

第24章 免責聲明

第25章 關於DelveInsight

目錄
Product Code: DIMI0806

DelveInsight's 'Biliary Tract Cancer (BTC)- Market Insights, Epidemiology, and Market Forecast-2030' report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of biliary tract cancer (BTC) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The biliary tract cancer market report provides current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted biliary tract cancer market Size from 2017 to 2030, segmented by seven major markets. The report also covers the current biliary tract cancer treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Biliary Tract Cancer: Disease Understanding and Treatment Algorithm

Biliary Tract Cancer Overview

Biliary Tract Cancer constitutes epithelial malignancies of the biliary tree and includes the following: gallbladder cancer (GBC), intrahepatic CCA (iCCA) and extrahepatic CCA (eCCA). The extrahepatic disease may be split into perihilar (Klatskin's tumor) and distal CCA. BTC constitutes approximately 3% of all gastrointestinal malignancies and is the most common hepatobiliary cancer after hepatocellular carcinoma. Primary sclerosing cholangitis (PSC), primary biliary cirrhosis (PBC), cirrhosis due to other causes, hepatitis C and congenital malformations such as choledochal cysts and multiple biliary papillomatosis are also associated with an increased risk of developing BTC. In addition, patients with germline mutations resulting in Lynch syndrome and BRCA1 and BRCA2 (breast cancer gene 1 and 2) genetic aberrations are also predisposed to BTC.

Gallbladder cancer originates in the cells of the gallbladder, and most are adenocarcinomas, which begin in the gland cells of the gallbladder lining. While, CCA is an epithelial malignancy originating from transformed cholangiocytes, with preclinical studies suggesting hepatic progenitor cells as the origin. iCCA can emerge at any point in the intrahepatic biliary tree, ranging from main bile ducts to the segmental bile ducts. In contrast to HCC, iCCA usually develops in non-cirrhotic liver. pCCA can arise in the right and/or left hepatic duct and/or at their junction (so-called perihilar bile ducts), and dCCA involves the common bile duct. The current term extrahepatic Cholangiocarcinoma (eCCA) is now discouraged from using as it combines subtypes with distinct clinicopathological features, origins, prognosis, and therapeutic options. Ampullary cancer originates in the area where the common bile duct meets the pancreatic duct, which is called the Ampulla of Vater.

Inflammation and cholestasis are key factors in cholangiocarcinogenesis. Next-generation sequencing has identified somatic mutations in oncogenes (i.e., KRAS), tumor suppressor (i.e., TP53 and SMAD4), and chromatin-modifying genes (i.e., ARID1A, BAP1, and PBMR1) in CCA. Furthermore, the tumor commonly metastasizes via lymphatic spread to the regional lymph nodes, followed by hematogenous metastasis to the liver, lungs, and peritoneum. The majority of cholangiocarcinomas are adenocarcinomas with variable grades of differentiation (mainly well-differentiated adenocarcinomas), although several uncommon types are also encountered, such as adenosquamous, squamous, mucinous, and anaplastic carcinomas. Jaundice and abdominal pain are the most common presentations of BTC.

A diagnosis of biliary tract cancer is usually based on the results of clinical examination of the abdomen, imaging scans using ultrasound, magnetic resonance imaging (MRI) or computed tomography (CT), and a biopsy. Further investigations can help to determine how advanced the cancer is (the 'stage'). For example, MRI of the biliary tract, a CT scan of the chest and an ultrasound scan of the lymph nodes are commonly used to see how far cancer has spread. Biliary tract cancer is staged according to tumor size, whether it has spread to the lymph nodes and whether it has spread into the liver, lungs or other parts of the body. This information is used to help decide the best treatment.

Treatment options for the early-stage disease include surgery followed by adjuvant chemotherapy. For patients with locally advanced disease, locoregional therapies (e.g., trans-arterial chemoembolization (TACE)) and external beam radiation therapy (EBRT) may be considered. However, these have not yet been validated in prospective randomized controlled trials, and therefore, their use is very variable. For patients with locally advanced and metastatic disease, the combination of gemcitabine and cisplatin has been shown to improve survival.

Biliary Tract Cancer Diagnosis and Treatment

It covers the details of conventional and current medical therapies and diagnosis available in the biliary tract cancer market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

The DelveInsight Biliary Tract Cancer market report gives a thorough understanding of biliary tract cancer by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides the treatment algorithms and treatment guidelines for biliary tract cancer in the US, Europe, and Japan.

Biliary Tract Cancer Epidemiology

The Biliary Tract Cancer epidemiology division provides insights about the historical and current patient pool along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

The disease epidemiology covered in the report provides historical and forecasted Biliary Tract Cancer epidemiology segmented as the total incident cases of biliary tract cancer, age-specific cases of biliary tract cancer, stage-specific cases of biliary tract cancer and mutation specific cases of biliary tract cancer. The report includes the incident scenario of Biliary Tract Cancer symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Country-wise Biliary Tract Cancer Epidemiology

The epidemiology segment also provides the Biliary Tract Cancer epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

The total incident population of biliary tract cancer in the 7MM countries was estimated to be 70,111 cases in 2017.

Biliary Tract Cancer Drug Chapters

The drug chapter segment of the Biliary tract cancer report encloses the detailed analysis of biliary tract cancer marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II and Phase-I/II) pipeline drugs. It also helps to understand the biliary tract cancer clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

Surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high.

Products detail in the report…

Biliary Tract Cancer Emerging Drugs

Ivosidenib (AG-120) (Agios Pharmaceuticals) is a first-in-class, oral, potent, reversible, targeted inhibitor of the mutant isocitrate dehydrogenase-1 (IDH1) enzyme. Agios Pharmaceuticals is developing Ivosidenib for the treatment of patients with cancers that harbor an IDH1 mutation. The company evaluated the product in late-stage clinical studies for cholangiocarcinoma with an IDH1 Mutation and presented the positive results of the phase III trial.

The company plans to submit a supplemental new drug application for Tibsovo in previously treated IDH1-mutant cholangiocarcinoma in the first quarter of 2021. Ivosidenib is marketed and commercialized under the brand name Tibsovo for Acute myeloid leukemia.

Infigratinib (BGJ398) (QED Therapeutics) is an investigational, orally administered FGFR1-3 tyrosine kinase inhibitor in development for the treatment of patients with FGFR-driven diseases, including cholangiocarcinoma (bile duct cancer) and others. It sparingly inhibits FGFR4; patients may tolerate it better than pan-FGFR1-4 inhibitors.

QED Therapeutics is developing Infigratinib in the phase III PROOF trial, in first Line Cholangiocarcinoma with FGFR2 Gene Fusions/Translocations and phase II in second-line cholangiocarcinoma (bile duct cancer). QED intends to submit an NDA with the US FDA for second and later-line cholangiocarcinoma in 2020. The FDA awarded infigratinib a Fast Track Designation for adults with first-line advanced or metastatic cholangiocarcinoma and an orphan drug designation for cholangiocarcinoma.

Products detail in the report…

Biliary Tract Cancer Market Outlook

The Biliary Tract Cancer market outlook of the report builds a detailed comprehension of the historical, current, and forecasted Biliary Tract Cancer market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers, and demand for better technology.

This segment gives a thorough detail of biliary tract cancer market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, biliary tract cancer market in the 7MM is expected to change in the study period 2017-2030.

The BTC market consists of various unmet needs, which include lack of treatment, poor understanding of molecular components involved in signaling pathways, and lack of awareness. Various research studies have focused on developing treatments for CCA to counter the current unmet needs of the market and provide better treatment options for CCA. With the continuous efforts in research and development, few companies are developing therapies

Key Findings

This section includes a glimpse of the biliary tract cancer market in the 7MM. The market size of biliary tract cancer in the seven major markets was found to be USD 904 Million in 2017.

The United States: Market Outlook

This section provides the total biliary tract cancer market size and market size by therapies of biliary tract cancer in the United States.

The United States accounts for the highest market size of biliary tract cancer in comparison to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

Hitherto, surgical treatments are the only potentially curative therapeutic options for all the subtypes of CCA. However, the majority of CCA patients are diagnosed at late-stage disease, and nearly more than one-fourth of patients considered resectable are found to be unresectable during explorative laparotomy. Few more aggressive surgical approaches and improved radiologic techniques have resulted in improved R0 (tumor-free margins) resection rates, but recurrence rates remain high.

As a part of palliative treatment, systemic chemotherapy is the treatment of choice for patients with locally advanced or inoperable disease Cisplatin/gemcitabine is the reference chemotherapy regimen.event.

Recently, with so much of efforts going into this area, Pemigatinib (Pemazyre) by Incyte Corporation was approved in the US and EU for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or another rearrangement as detected by an FDA-approved test.

EU-5 Countries: Market Outlook

The total biliary tract cancer market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

Japan Market Outlook

The total biliary tract cancer market size and market size by therapies of biliary tract cancer in Japan are also mentioned.

Biliary Tract Cancer Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2017-2030. The analysis covers biliary tract cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Biliary Tract Cancer Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II and Phase I/II stage. It also analyses biliary tract cancer key players involved in developing targeted therapeutics.

Major players include QED Therapeutics, Delcath Systems, Taiho Oncology, Merck Sharp & Dohme, Agios Pharmaceuticals, whose key products are expected to get launched in the US market by 20XX.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition, and merger, licensing, and patent details for biliary tract cancer emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SME's opinion working in Biliary Tract Cancer domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Biliary Tract Cancer market trend. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform Competitive and Market Intelligence analysis of the Biliary Tract Cancer market by using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report:

  • The report covers the descriptive overview of biliary tract cancer, explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight has been provided into the biliary tract cancer epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for biliary tract cancer is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of biliary tract cancer market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global biliary tract cancer market

Report Highlights:

  • In the coming years, biliary tract cancer market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence biliary tract cancer R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for biliary tract cancer. The launch of emerging therapies will significantly impact the biliary tract cancer market
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for biliary tract cancer.
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Biliary Tract Cancer Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Biliary Tract Cancer Pipeline Analysis
  • Biliary Tract Cancer market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Biliary Tract Cancer Report Key Strengths

  • 11-years Forecast
  • 7MM Coverage
  • Biliary Tract Cancer Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Biliary Tract Cancer Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness
  • Market Drivers and Barriers

Key Questions:

Market Insights:

  • What were the biliary tract cancer Market share (%) distribution in 2017, and how would it look like in 2030?
  • What would be the biliary tract cancer total market Size and market Size by therapies across the 7MM during the forecast period (2017-2030)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest biliary tract cancer market Size during the forecast period (2017-2030)?
  • At what CAGR, the biliary tract cancer market is expected to grow in the 7MM during the forecast period (2017-2030)?
  • What would be the biliary tract cancer market outlook across the 7MM during the forecast period (2017-2030)?
  • What would be the biliary tract cancer market growth till 2030, and what will be the resultant market Size in the year 2030?
  • How would the market drivers, barriers, and future opportunities affect the market dynamics and subsequent analysis of the associated trends?

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of the biliary tract cancer?
  • What is the historical biliary tract cancer patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan?
  • What would be the forecasted patient pool of biliary tract cancer in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to biliary tract cancer?
  • Out of all 7MM countries, which country would have the highest incident of biliary tract cancer during the forecast period (2017-2030)?
  • At what CAGR the population is expected to grow in the 7MM during the forecast period (2017-2030)?

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of biliary tract cancer?
  • What are the current treatment guidelines for treating biliary tract cancer in the USA, Europe, and Japan?
  • What are the biliary tract cancer marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, and efficacy, etc.?
  • How many companies are developing therapies for the treatment of biliary tract cancer?
  • How many therapies are developed by each company for the treatment of biliary tract cancer?
  • How many emerging therapies are in the mid-stage and late stages of development for the treatment of biliary tract cancer?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the biliary tract cancer therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for biliary tract cancer and their status?
  • What are the key designations that have been granted for the emerging therapies for biliary tract cancer?
  • What are the global historical and forecasted market for biliary tract cancer?

Reasons to buy:

  • The report will help in developing business strategies by understanding trends shaping and driving the biliary tract cancer market
  • To understand the future market competition in the biliary tract cancer market and Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for biliary tract cancer in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for biliary tract cancer market.
  • To understand the future market competition in the biliary tract cancer market.

Table of Contents

1. Key Insights

2. Biliary Tract Cancer (BTC): Market Overview at a Glance

  • 2.1. Market Share (%) Distribution of BTC in 2017
  • 2.2. Market Share (%) Distribution of BTC in 2030

3. Executive Summary

4. Organizations

5. Biliary tract cancer (BTC): Disease Background and Overview

  • 5.1. Introduction
  • 5.2. Classification of Cholangiocarcinomas
  • 5.3. Staging
    • 5.3.1. Intrahepatic CCA (iCCA)
    • 5.3.2. Perihilar CCA
    • 5.3.3. Distal extrahepatic
    • 5.3.4. Gall Bladder Cancer
  • 5.4. Symptoms
  • 5.5. Etiology
  • 5.6. Pathogenesis
  • 5.7. Biomarkers
  • 5.8. Diagnosis
    • 5.8.1. Diagnosis of Intrahepatic CCA
    • 5.8.2. Diagnosis of Perihilar and Distal CCA
    • 5.8.3. Diagnosis of Gall Bladder Cancer
    • 5.8.4. Guidelines for the diagnosis of intrahepatic cholangiocarcinoma
    • 5.8.5. ESMO Clinical Practice Guidelines for diagnosis for Biliary tract Cancer

6. Epidemiology and Patient Population

  • 6.1. Key Findings
  • 6.2. 7MM Total Incident Patient Population of BTC
  • 6.3. Assumptions and Rationale: 7MM
  • 6.4. United States Epidemiology
    • 6.4.1. Total Incident Cases of Biliary tract cancers (BTC) in the United States
    • 6.4.2. Age-specific Cases of Biliary tract cancers (BTC) in the United States
    • 6.4.3. Mutation-specific Cases of Biliary tract cancers (BTC) in the United States
    • 6.4.4. Stage-specific Cases of Biliary tract cancers (BTC) in the United States
  • 6.5. Germany Epidemiology
    • 6.5.1. Total Incident Cases of Biliary tract cancers (BTC) in Germany
    • 6.5.2. Age-specific Cases of Biliary tract cancers (BTC) in Germany
    • 6.5.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Germany
    • 6.5.4. Stage-specific Cases of Biliary tract cancers (BTC) in Germany
  • 6.6. France Epidemiology
    • 6.6.1. Total Incident Cases of Biliary tract cancers (BTC) in France
    • 6.6.2. Age-specific Cases of Biliary tract cancers (BTC) in France
    • 6.6.3. Mutation-specific Cases of Biliary tract cancers (BTC) in France
    • 6.6.4. Stage-specific Cases of Biliary tract cancers (BTC) in France
  • 6.7. Italy Epidemiology
    • 6.7.1. Total Incident Cases of Biliary tract cancers (BTC) in Italy
    • 6.7.2. Age-specific Cases of Biliary tract cancers (BTC) in Italy
    • 6.7.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Italy
    • 6.7.4. Stage-specific Cases of Biliary tract cancers (BTC) in Italy
  • 6.8. Spain Epidemiology
    • 6.8.1. Total Incident Cases of Biliary tract cancers (BTC) in Spain
    • 6.8.2. Age-specific Cases of Biliary tract cancers (BTC) in Spain
    • 6.8.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Spain
    • 6.8.4. Stage-specific Cases of Biliary tract cancers (BTC) in Spain
  • 6.9. UK Epidemiology
    • 6.9.1. Total Incident Cases of Biliary tract cancers (BTC) in UK
    • 6.9.2. Age-specific Cases of Biliary tract cancers (BTC) in UK
    • 6.9.3. Mutation-specific Cases of Biliary tract cancers (BTC) in UK
    • 6.9.4. Stage-specific Cases of Biliary tract cancers (BTC) in UK
  • 6.10. Japan Epidemiology
    • 6.10.1. Total Incident Cases of Biliary tract cancers (BTC) in Japan
    • 6.10.2. Age-specific Cases of Biliary tract cancers (BTC) in Japan
    • 6.10.3. Mutation-specific Cases of Biliary tract cancers (BTC) in Japan
    • 6.10.4. Stage-specific Cases of Biliary tract cancers (BTC) in Japan

7. Therapies and Treatment strategies

    • 7.1.1. Treatment Recommendations - British Society of Gastroenterology guidelines
    • 7.1.2. Guidelines for the treatment of Intrahepatic Cholangiocarcinoma
    • 7.1.3. ESMO Clinical Practice Guidelines for Treatment and Follow-up for Biliary Tract Cancer
    • 7.1.4. NCCN Guidelines for Hepatobiliary Cancer 2020
    • 7.1.5. Treatment Algorithm

8. Patient Journey

9. Research Priorities

10. Unmet Needs

11. Marketed Drugs

  • 11.1. Pemigatinib: Incyte Corporation
    • 11.1.1. Drug Description
    • 11.1.2. Regulatory Approval
    • 11.1.3. Other Developmental Activities
    • 11.1.4. Clinical Development
    • 11.1.5. Safety and Efficacy
    • 11.1.6. Product Profile
  • 11.2. Larotrectinib: Loxo Oncology/Bayer
    • 11.2.1. Drug Description
    • 11.2.2. Regulatory Approval
    • 11.2.3. Other Developmental Activities
    • 11.2.4. Clinical Development
    • 11.2.5. Safety and Efficacy
    • 11.2.6. Product Profile
  • 11.3. Entrectinib: Roche
    • 11.3.1. Product Description
    • 11.3.2. Regulatory Approval
    • 11.3.3. Other Developmental Activities
    • 11.3.4. Clinical Development
    • 11.3.5. Safety and Efficacy
    • 11.3.6. Product Profile

12. Emerging Therapies

    • 12.1.1. Key cross competition
  • 12.2. Ivosidenib: Agios Pharmaceuticals
    • 12.2.1. Product Description
    • 12.2.2. Other Developmental Activities
    • 12.2.3. Clinical Development
    • 12.2.4. Safety and Efficacy
    • 12.2.5. Product Profile
  • 12.3. Infigratinib: QED Therapeutics
    • 12.3.1. Drug Description
    • 12.3.2. Other Developmental Activities
    • 12.3.3. Clinical Development
    • 12.3.4. Safety and Efficacy
    • 12.3.5. Product Profile
  • 12.4. Melphalan: Delcath Systems
    • 12.4.1. Drug Description
    • 12.4.2. Other Developmental Activities
    • 12.4.3. Clinical Development
    • 12.4.4. Safety and Efficacy
    • 12.4.5. Product Profile
  • 12.5. Derazantinib: Basilea Pharmaceutica
    • 12.5.1. Drug Description
    • 12.5.2. Other Developmental Activities
    • 12.5.3. Clinical Development
    • 12.5.4. Safety and Efficacy
    • 12.5.5. Product Profile
  • 12.6. Regorafenib: Bayer
    • 12.6.1. Drug Description
    • 12.6.2. Other Developmental Activities
    • 12.6.3. Clinical Development
    • 12.6.4. Safety and Efficacy
    • 12.6.5. Product Profile
  • 12.7. Erdafitinib: Janssen Pharmaceutical
    • 12.7.1. Product Description
    • 12.7.2. Other Developmental Activities
    • 12.7.3. Clinical Development
    • 12.7.4. Safety and Efficacy
    • 12.7.5. Product Profile
  • 12.8. Opaganib: RedHill Biopharma
    • 12.8.1. Product Description
    • 12.8.2. Other Developmental Activities
    • 12.8.3. Clinical Development
    • 12.8.4. Safety and Efficacy
    • 12.8.5. Product Profile
  • 12.9. Fimaporfin: PCI biotech
    • 12.9.1. Product Description
    • 12.9.2. Other Developmental Activities
    • 12.9.3. Clinical Development
    • 12.9.4. Safety and Efficacy
    • 12.9.5. Product Profile
  • 12.10. KA2507: Karus Therapeutics
    • 12.10.1. Product Description
    • 12.10.2. Clinical Development
    • 12.10.3. Safety and Efficacy
    • 12.10.4. Product Profile
  • 12.11. Lenvatinib: Eisai
    • 12.11.1. Product Description
    • 12.11.2. Other Developmental Activities
    • 12.11.3. Clinical Development
    • 12.11.4. Safety and Efficacy
    • 12.11.5. Product Profile
  • 12.12. Telotristat ethyl: Lexicon Pharmaceuticals/TerSera Therapeutics
    • 12.12.1. Product Description
    • 12.12.2. Other Developmental Activities
    • 12.12.3. Clinical Development
    • 12.12.4. Safety and Efficacy
    • 12.12.5. Product Profile
  • 12.13. DKN-01: Leap Therapeutics
    • 12.13.1. Product Description
    • 12.13.2. Other Developmental Activities
    • 12.13.3. Clinical Development
    • 12.13.4. Safety and Efficacy
    • 12.13.5. Product Profile
  • 12.14. Niraparib (Zejula): GlaxoSmithKline
    • 12.14.1. Product Description
    • 12.14.2. Other Developmental Activities
    • 12.14.3. Clinical Development
    • 12.14.4. Product Profile
  • 12.15. E7090: Eisai
    • 12.15.1. Product Description
    • 12.15.2. Other Developmental Activities
    • 12.15.3. Clinical Development
    • 12.15.4. Safety and Efficacy
    • 12.15.5. Product Profile
  • 12.16. A166: KLUS Pharma
    • 12.16.1. Product Description
    • 12.16.2. Clinical Development
    • 12.16.3. Safety and Efficacy
    • 12.16.4. Product Profile
  • 12.17. Durvalumab: AstraZeneca
    • 12.17.1. Product Description
    • 12.17.2. Other developmental activities
    • 12.17.3. Clinical Development
    • 12.17.4. Safety and Efficacy
    • 12.17.5. Product Profile
  • 12.18. Pembrolizumab: Merck Sharp & Dohme Corp.
    • 12.18.1. Product description
    • 12.18.2. Other development activities
    • 12.18.3. Clinical development
    • 12.18.4. Safety and Efficacy
    • 12.18.5. Product Profile
  • 12.19. Futibatinib: Taiho Oncology
    • 12.19.1. Drug Description
    • 12.19.2. Other Developmental Activities
    • 12.19.3. Clinical Development
    • 12.19.4. Safety and Efficacy
    • 12.19.5. Product Profile
  • 12.20. Nab-paclitaxel: Celgene
    • 12.20.1. Product description
    • 12.20.2. Other Development Activities
    • 12.20.3. Clinical Development
    • 12.20.4. Safety and Efficacy
    • 12.20.5. Product Profile
  • 12.21. Surufatinib: Hutchison Medipharma Limited
    • 12.21.1. Product Description
    • 12.21.2. Clinical Development
    • 12.21.3. Safety and Efficacy
    • 12.21.4. Product Profile
  • 12.22. Bintrafusp Alfa: Merck Sharp & Dohme Corp.
    • 12.22.1. Product Description
    • 12.22.2. Other Developmental Activities
    • 12.22.3. Clinical Development
    • 12.22.4. Safety and Efficacy
    • 12.22.5. Product Profile
  • 12.23. Entinostat: Syndax Pharmaceuticals
    • 12.23.1. Product Description
    • 12.23.2. Clinical development
    • 12.23.3. Product Profile
  • 12.24. Zanidatamab: BeiGene
    • 12.24.1. Product Description
    • 12.24.2. Other Developmental Activities
    • 12.24.3. Clinical Development
    • 12.24.4. Safety and Efficacy
    • 12.24.5. Product Profile
  • 12.25. Nivolumab: Bristol-Myers Squibb
    • 12.25.1. Product Description
    • 12.25.2. Other Developmental Activities
    • 12.25.3. Clinical Development
    • 12.25.4. Safety and Efficacy
    • 12.25.5. Product Profile
  • 12.26. TAS 102: Taiho Pharma
    • 12.26.1. Product Description
    • 12.26.2. Other Developmental Activities
    • 12.26.3. Clinical Development
    • 12.26.4. Safety and Efficacy
    • 12.26.5. Product Profile
  • 12.27. Nanoliposomal irinotecan: Ipsen
    • 12.27.1. Product Description
    • 12.27.2. Other Developmental Activities
    • 12.27.3. Clinical Development
    • 12.27.4. Safety and Efficacy
    • 12.27.5. Product Profile
  • 12.28. Trastuzumab deruxtecan (T-DXd): Daiichi Sankyo
    • 12.28.1. Product Description
    • 12.28.2. Other Developmental Activities
    • 12.28.3. Clinical Development
    • 12.28.4. Safety and Efficacy
    • 12.28.5. Product Profile
  • 12.29. NUC-1031: NuCana
    • 12.29.1. Product Description
    • 12.29.2. Other Developmental Activities
    • 12.29.3. Clinical Development
    • 12.29.4. Safety and Efficacy
    • 12.29.5. Product Profile

13. Biliary Tract Cancer: Market Outlook

  • 13.1. Key Findings
  • 13.2. Market Size of BTC in 7MM

14. Market Outlook: 7MM

  • 14.1. United States Market Size
    • 14.1.1. Total Market size of BTC in the US
    • 14.1.2. Market Size by Therapies for Early Stage Disease
    • 14.1.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.1.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.2. Germany Market Size
    • 14.2.1. Total Market size of BTC in Germany
    • 14.2.2. Market Size by Therapies for Early Stage Disease
    • 14.2.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.2.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.3. France Market Size
    • 14.3.1. Total Market size of BTC in France
    • 14.3.2. Market Size by Therapies for Early Stage Disease
    • 14.3.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.3.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.4. Italy Market Size
    • 14.4.1. Total Market size of BTC in Italy
    • 14.4.2. Market Size by Therapies for Early Stage Disease
    • 14.4.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.4.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.5. Spain Market Size
    • 14.5.1. Total Market size of BTC in Spain
    • 14.5.2. Market Size by Therapies for Early Stage Disease
    • 14.5.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.5.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.6. UK Market Size
    • 14.6.1. Total Market size of BTC in UK
    • 14.6.2. Market Size by Therapies for Early Stage Disease
    • 14.6.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.6.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases
  • 14.7. Japan Market Size
    • 14.7.1. Total Market size of BTC in Japan
    • 14.7.2. Market Size by Therapies for Early Stage Disease
    • 14.7.3. Market Size by Therapies in First-line Advanced and Metastatic Cases
    • 14.7.4. Market Size by Therapies in Second-line Advanced and Metastatic Cases

15. Market Drivers

16. Market Barriers

17. Reimbursement and Market Access

18. SWOT Analysis

19. Case studies

  • 19.1. A Case Report of Intrahepatic Cholangiocarcinoma in a Young Male
  • 19.2. A new potential immunotherapy drug for solid tumor: A case study
  • 19.3. A case of distal extrahepatic cholangiocarcinoma with two positive resection margins

20. KOL Views

21. Appendix

22. Report Methodology

23. DelveInsight Capabilities

24. Disclaimer

25. About DelveInsight

List of Tables

  • Table 1: TNM and AJCC/ UICC Staging Systems for iCCA
  • Table 2: AJCC staging of iCCA: Comparison of 7th and 8th editions
  • Table 3: TNM and AJCC/UICC Staging Systems for Perihilar and Distal CCA
  • Table 4: TNM and AJCC/UICC Staging Systems for Gall Bladder Cancer
  • Table 5: Risk Factors for BTC
  • Table 6: Host genetic polymorphism associated with cholangiocarcinoma
  • Table 7: Recommendations of ICCA for Diagnosis
  • Table 8: ESMO Clinical Practice Guidelines for treatment and follow-up
  • Table 9: Total Incident Cases of Biliary tract cancers in the 7MM (2017-2030)
  • Table 10: Total Incident Cases of BTC in the US (2017-2030)
  • Table 11: Age-specific Cases of BTC in the US (2017-2030)
  • Table 12: Mutation-specific Cases of BTC in the US (2017-2030)
  • Table 13: Stage-specific Cases of BTC in the US (2017-2030)
  • Table 14: Total Incident Cases of BTC in Germany (2017-2030)
  • Table 15: Age-specific Cases of BTC in Germany (2017-2030)
  • Table 16: Mutation-specific Cases of BTC in Germany (2017-2030)
  • Table 17: Stage-specific Cases of BTC in Germany (2017-2030)
  • Table 18: Total Incident Cases of BTC in France (2017-2030)
  • Table 19: Age-specific Cases of BTC in France (2017-2030)
  • Table 20: Mutation-specific Cases of BTC in France (2017-2030)
  • Table 21: Stage-specific Cases of BTC in France (2017-2030)
  • Table 22: Total Incident Cases of BTC in Italy (2017-2030)
  • Table 23: Age-specific Cases of BTC in Italy (2017-2030)
  • Table 24: Mutation-specific Cases of BTC in Italy (2017-2030)
  • Table 25: Stage-specific Cases of BTC in Italy (2017-2030)
  • Table 26: Total Incident Cases of BTC in Spain (2017-2030)
  • Table 27: Age-specific Cases of BTC in Spain (2017-2030)
  • Table 28: Mutation-specific Cases of BTC in Spain (2017-2030)
  • Table 29: Stage-specific Cases of BTC in Spain (2017-2030)
  • Table 30: Total Incident Cases of BTC in UK (2017-2030)
  • Table 31: Age-specific Cases of BTC in UK (2017-2030)
  • Table 32: Mutation-specific Cases of BTC in UK (2017-2030)
  • Table 33: Stage-specific Cases of BTC in UK (2017-2030)
  • Table 34: Total Incident Cases of BTC in Japan (2017-2030)
  • Table 35: Age-specific Cases of BTC in Japan (2017-2030)
  • Table 36: Mutation-specific Cases of BTC in Japan (2017-2030)
  • Table 37: Stage-specific Cases of BTC in Japan (2017-2030)
  • Table 38: Recommendations of the British Society of Gastroenterology guidelines
  • Table 39: Recommendations of iCCA for management
  • Table 40: Levels of evidence and grades of recommendation
  • Table 41: ESMO Clinical Practice Guidelines for treatment and follow-up
  • Table 42: ESMO Clinical Practice Guidelines for treatment and follow-up
  • Table 43: NCCN Guidelines for Hepatobiliary Cancer 2020

Table:44 NCCN Guidelines for Principles of Systemic Therapy**

  • Table 45:: INCB054828, Clinical Trial Description, 2020
  • Table 46: Larotrectinib, Clinical Trial Description, 2020
  • Table 47: Entrectinib, Clinical Trial Description, 2020
  • Table 48: Key Cross: Emerging Therapies (III& II/III)
  • Table 49: Key Cross: Emerging Therapies (II& I/II)
  • Table 50: AG-120, Clinical Trial Description, 2020
  • Table 51: BGJ398, Clinical Trial Description, 2020
  • Table 52: Melphalan/HDS, Clinical Trial Description, 2020
  • Table 53: Derazantinib, Clinical Trial Description, 2020
  • Table 54: Regorafenib, Clinical Trial Description, 2020
  • Table 55: Erdafitinib, Clinical Trial Description, 2020
  • Table 56: Opaganib, Clinical Trial Description, 2020
  • Table 57: Fimaporfin; Clinical Trial Description, 2020
  • Table 58: KA2507; Clinical Trial Description, 2020
  • Table 59: Lenvatinib; Clinical Trial Description, 2020
  • Table 60 Telotristat ethyl; Clinical Trial Description, 2020
  • Table 61 DKN-01; Clinical Trial Description, 2020
  • Table 62: Niraparib Clinical Trial Description, 2020
  • Table 63: E7090, Clinical Trial Description, 2020
  • Table 64: A166, Clinical Trial Description, 2020
  • Table 65: Durvalumab, Clinical Trial Description, 2020

Table: 66 Pembrolizumab, Clinical Trial Description, 2020

  • Table 67: Futibatinib, Clinical Trial Description, 2020
  • Table 68: Bintrafusp Alfa, Clinical Trial Description, 2020
  • Table 69: Entinostat, Clinical Trial Description, 2020
  • Table 70: Zanidatamab, Clinical Trial Description, 2020
  • Table 71: Nivolumab, Clinical Trial Description, 2020
  • Table 72: TAS-102 Clinical Trial Description, 2020
  • Table 73: Nanoliposomal irinotecan, Clinical Trial Description, 2020
  • Table 74: T-DXd, Clinical Trial Description, 2020
  • Table 75: NUC-1031, Clinical Trial Description, 2020
  • Table 76: Seven Major Market Size of BTC in USD Million (2017-2030)
  • Table 77: The US Market Size of BTC in USD Million (2017-2030)
  • Table 78: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017-2030)
  • Table 79: Market Size of BTC by First Line in the US in USD Million (2017-2030)
  • Table 80: Market Size of BTC by Second Line in the US in USD Million (2017-2030)
  • Table 81: Germany Market Size of BTC in USD Million (2017-2030)
  • Table 82: Market Size by Therapies for Early Stage Disease in Germany in USD Million (2017-2030)
  • Table 83: Market Size of BTC by First Line in Germany in USD Million (2017-2030)
  • Table 84: Market Size of BTC by Second Line in Germany in USD Million (2017-2030)
  • Table 85: France Market Size of BTC in USD Million (2017-2030)
  • Table 86: Market Size by Therapies for Early Stage Disease in France in USD Million (2017-2030)
  • Table 87: Market Size of BTC by First Line in France in USD Million (2017-2030)
  • Table 88: Market Size of BTC by Second Line in France in USD Million (2017-2030)
  • Table 89: Italy Market Size of BTC in USD Million (2017-2030)
  • Table 90: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017-2030)
  • Table 91: Market Size of BTC by First Line in Italy in USD Million (2017-2030)
  • Table 92: Market Size of BTC by Second Line in Italy in USD Million (2017-2030)
  • Table 93: Spain Market Size of BTC in USD Million (2017-2030)
  • Table 94: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017-2030)
  • Table 95: Market Size of BTC by First Line in Spain in USD Million (2017-2030)
  • Table 96: Market Size of BTC by Second Line in Spain in USD Million (2017-2030)
  • Table 97: UK Market Size of BTC in USD Million (2017-2030)
  • Table 98: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017-2030)
  • Table 99: Market Size of BTC by First Line in UK in USD Million (2017-2030)
  • Table 100: Market Size of BTC by Second Line in UK in USD Million (2017-2030)
  • Table 101: Japan Market Size of BTC in USD Million (2017-2030)
  • Table 102: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017-2030)
  • Table 103: Market Size of BTC by First Line in Japan in USD Million (2017-2030)
  • Table 104:Market Size of BTC by Second Line in Japan in USD Million (2017-2030)

List of Figures

  • Figure 1: Risk factors and molecular alterations of BTC
  • Figure 2: Possible Risk Factor and Symptoms
  • Figure 3: Cells of origin in Cholangiocarcinoma (CCA)
  • Figure 4: Chronic Inflammation Cycle
  • Figure 5: Components of the tumor microenvironment in CCA
  • Figure 6: Factors secreted by cancer-associated fibroblasts
  • Figure 7: Intracellular pathways involved in CCA proliferation and apoptosis
  • Figure 8: Common driver genes in HCC and CCA
  • Figure 9: Molecular genetics of BTC
  • Figure 10: Algorithm for management and diagnosis of intrahepatic CCA
  • Figure 11: Algorithm for management and diagnosis of perihilar cholangiocarcinoma
  • Figure 12: Total Cases of Biliary tract cancers (BTC) in the 7MM (2017-2030)
  • Figure 13: Total Incident Cases of BTC in the US (2017-2030)
  • Figure 14: Age-specific Cases of BTC in the US (2017-2030)
  • Figure 15: Mutation-specific Cases of BTC in the US (2017-2030)
  • Figure 16: Stage-specific Cases of BTC in the US (2017-2030)
  • Figure 17: Total Incident Cases of BTC in Germany (2017-2030)
  • Figure 18: Age-specific Cases of BTC in Germany (2017-2030)
  • Figure 19: Mutation-specific Cases of BTC in Germany (2017-2030)
  • Figure 20: Stage-specific Cases of BTC in Germany (2017-2030)
  • Figure 21: Total Incident Cases of BTC in France (2017-2030)
  • Figure 22: Age-specific Cases of BTC in France (2017-2030)
  • Figure 23: Mutation-specific Cases of BTC in France (2017-2030)
  • Figure 24: Stage-specific Cases of BTC in France (2017-2030)
  • Figure 25: Total Incident Cases of BTC in Italy (2017-2030)
  • Figure 26: Age-specific Cases of BTC in Italy (2017-2030)
  • Figure 27: Mutation-specific Cases of BTC in Italy (2017-2030)
  • Figure 28: Stage-specific Cases of BTC in Italy (2017-2030)
  • Figure 29: Total Incident Cases of BTC in Spain (2017-2030)
  • Figure 30: Age-specific Cases of BTC in Spain (2017-2030)
  • Figure 31: Mutation-specific Cases of BTC in Spain (2017-2030)
  • Figure 32: Stage-specific Cases of BTC in Spain (2017-2030)
  • Figure 33: Total Incident Cases of BTC in UK (2017-2030)
  • Figure 34: Age-specific Cases of BTC in UK (2017-2030)
  • Figure 35: Mutation-specific Cases of BTC in UK (2017-2030)
  • Figure 36: Stage-specific Cases of BTC in UK (2017-2030)
  • Figure 37: Total Incident Cases of BTC in Japan (2017-2030)
  • Figure 38: Age-specific Cases of BTC in Japan (2017-2030)
  • Figure 39: Mutation-specific Cases of BTC in Japan (2017-2030)
  • Figure 40: Stage-specific Cases of BTC in Japan (2017-2030)
  • Figure 41: Algorithm for diagnosis and management of Biliary Tract Cancer
  • Figure 42: A suggested algorithm for the diagnosis and Treatment of cholangiocarcinomas
  • Figure 43: A suggested treatment algorithm for patients with iCCA
  • Figure 44: Algorithm for diagnosis and management of dCCA
  • Figure 45: Flowchart - Management and treatment of patients suspected of perihilar CCA
  • Figure 46: A suggested diagnosis and treatment algorithm for Gallbladder Cancer
  • Figure 47: Unmet Needs of Cholangiocarcinoma (CCA)
  • Figure 48: 7 Major Market Size of BTC in USD Million (2017-2030)
  • Figure 49: Market Size of BTC in the US, USD Millions (2017-2030)
  • Figure 50: Market Size by Therapies for Early Stage Disease in the US in USD Million (2017-2030)
  • Figure 51: Market Size of BTC by First Line in the US in USD Million (2017-2030)
  • Figure 52: Market Size of BTC by Second Line in the US in USD Million (2017-2030)
  • Figure 53: Market Size of BTC in Germany, USD Millions (2017-2030)
  • Figure 54: Market Size for Early Stage Disease in Germany in USD Million (2017-2030)
  • Figure 55: Market Size of BTC by First Line in Germany in USD Million (2017-2030)
  • Figure 56: Market Size of BTC by Second Line in Germany in USD Million (2017-2030)
  • Figure 57: Market Size of BTC in France, USD Millions (2017-2030)
  • Figure 58: Market Size by Therapies for Early Stage Disease in France in USD Million (2017-2030)
  • Figure 59: Market Size of BTC by First Line in France in USD Million (2017-2030)
  • Figure 60: Market Size of BTC by Second Line in France in USD Million (2017-2030)
  • Figure 61: Market Size of BTC in Italy, USD Millions (2017-2030)
  • Figure 62: Market Size by Therapies for Early Stage Disease in Italy in USD Million (2017-2030)
  • Figure 63: Market Size of BTC by First Line in Italy in USD Million (2017-2030)
  • Figure 64: Market Size of BTC by Second Line in Italy in USD Million (2017-2030)
  • Figure 65: Market Size of BTC in Spain, USD Millions (2017-2030)
  • Figure 66: Market Size by Therapies for Early Stage Disease in Spain in USD Million (2017-2030)
  • Figure 67: Market Size of BTC by First Line in Spain in USD Million (2017-2030)
  • Figure 68: Market Size of BTC by Second Line in Spain in USD Million (2017-2030)
  • Figure 69: Market Size of BTC in UK, USD Millions (2017-2030)
  • Figure 70: Market Size by Therapies for Early Stage Disease in UK in USD Million (2017-2030)
  • Figure 71: Market Size of BTC by First Line in UK in USD Million (2017-2030)
  • Figure 72: Market Size of BTC by Second Line in UK in USD Million (2017-2030)
  • Figure 73: Market Size of BTC in Japan, USD Millions (2017-2030)
  • Figure 74: Market Size by Therapies for Early Stage Disease in Japan in USD Million (2017-2030)
  • Figure 75: Market Size of BTC by First Line in Japan in USD Million (2017-2030)
  • Figure 76: Market Size of BTC by Second Line in Japan in USD Million (2017-2030)
  • Figure 77: Market Drivers
  • Figure 78:Market Barriers
  • Figure 79: SWOT Analysis of Biliary Tract Cancer